Sean Jordan – Page 4

April 27, 2024

Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections

Most repurposed drugs have proved ineffective for treating COVID-19. We evaluated median effective and toxic concentrations (EC(50), CC(50)) of 49 drugs, mostly from previous clinical trials, in Vero cells. Ratios of reported unbound peak plasma concentrations, (C(max))/EC(50), were used to predict the potential in vivo efficacy. The 20 drugs with the highest ratios were retested in human Calu-3 and Caco-2 cells, and their CC(50) was determined in an expanded panel of cell lines. Many of the 20...

April 12, 2024

Marina and Denis Win Awards at AWSOM 2024

Congratulations to Marina Michaud and Denis Ohlstrom, who received awards at the 2024 Atlanta Workshop for Single-Cell Omics (AWSOM)! Marina Michaud received the award for best oral presentation for her work titled “Integrated single-nuclei and spatial transcriptomic approach reveals acute endothelial injury during vein grafting procedures validated by RNAScope”, and Denis Ohlstrom received the award for the best poster presentation for his work titled “Single cell meta-analysis of 168 pediatric acute myeloid leukemia samples uncovers treatment resistant stem and mast cells”.

April 12, 2024

Bhasin Lab Attends AWSOM 2024!

The Bhasin Lab had an overwhelming presence at the 2024 Atlanta Workshop for Single-Cell Omics (AWSOM). This conference featured speakers from all over the country that are spearheading the latest innovations in single-cell sequencing and research as well as student presenters who are making a remarkable impact in their field. Two of our lab members gave oral presentations at the conference: Marina Michaud – Integrated single-nuclei and spatial transcriptomic approach reveals acute endothelial injury during vein grafting procedures validated by […]

April 8, 2024

Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin

Wilms tumor (WT) is the most common renal malignancy of childhood. Despite improvements in the overall survival, relapse occurs in ~15% of patients with favorable histology WT (FHWT). Half of these patients will succumb to their disease. Identifying novel targeted therapies remains challenging in part due to the lack of faithful preclinical in vitro models. Here we establish twelve patient-derived WT cell lines and demonstrate that these models faithfully recapitulate WT biology using genomic...